170 related articles for article (PubMed ID: 28471803)
1. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
Kim S; Shin C; Jee SH
Gene; 2015 Feb; 556(2):199-205. PubMed ID: 25434496
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
Sun J; Tao S; Gao Y; Peng T; Tan A; Zhang H; Yang X; Qin X; Hu Y; Feng J; Kim ST; Lin X; Wu Y; Zhang J; Li Z; Li L; Mo L; Liang Z; Shi D; Huang Z; Huang X; Liu M; Liu Q; Zhang S; Lilly Zheng S; Xu J; Mo Z
Hum Genet; 2013 Apr; 132(4):423-9. PubMed ID: 23269536
[TBL] [Abstract][Full Text] [Related]
5. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
6. Genetic correction of PSA values using sequence variants associated with PSA levels.
Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
[TBL] [Abstract][Full Text] [Related]
7. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.
Hill OT; Mason TJ; Schwartz SW; Foulis PR
BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Choi WS; Kim D; Kim HJ; Myung SC
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):149-56. PubMed ID: 24492489
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
[TBL] [Abstract][Full Text] [Related]
10. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
11. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
Beikzadeh B; Angaji SA; Abolhasani M
BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
[TBL] [Abstract][Full Text] [Related]
12. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.
Gilbert R; Martin RM; Evans DM; Tilling K; Davey Smith G; Kemp JP; Lane JA; Hamdy FC; Neal DE; Donovan JL; Metcalfe C
PLoS One; 2015; 10(10):e0136735. PubMed ID: 26431041
[TBL] [Abstract][Full Text] [Related]
14. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
Bensen JT; Xu Z; Smith GJ; Mohler JL; Fontham ET; Taylor JA
Prostate; 2013 Jan; 73(1):11-22. PubMed ID: 22549899
[TBL] [Abstract][Full Text] [Related]
16. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
19. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
